|ANI Pharmaceuticals -- USA Stock|| |
USD 61.14 0.50 0.82%
VP of Operations
Mr. James G. Marken is Vice President Operations of the Company. He has served as the Companys Vice President, Operations, since June 2013 and was promoted to Senior Vice President, Operations and Product Development in May 2016. Mr. Marken joined ANIP in March 2007 as General Manager of the Minnesota facilities. As Vice President, Operations and Product Development, Mr. Marken was principally responsible for the following areas manufacturing, packaging, engineeringmaintenance, purchasing, and warehousing. Mr. Marken brings over 20 years of pharmaceutical industry experience to the Company. Prior to joining ANIP in March 2007, he worked for Solvay Pharmaceuticals as plant manager and in various departments including quality control, validation and manufacturing
Age: 53 VP Since 2013
Marken holds a B.S. degree in Chemistry from Bemidji State University.
The company has return on total asset (ROA)
of 6.74 %
which means that it generated profit of $6.74 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE)
of (0.63) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 201.51 M in liabilities with Debt to Equity (D/E) ratio of 115.3 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. ANI Pharmaceuticals has Current Ratio of 3.29 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States. ANI Pharmaceuticals, Inc. is headquartered in Baudette, Minnesota. ANI Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 173 people.ANI Pharmaceuticals (ANIP) is traded on NASDAQ General Markets in USA. It is located in MINNESOTA, U.S.A and employs 173 people. ANI Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
ANI Pharmaceuticals Leadership Team
|Robert Brown, Chairman, MBA|
|Charlotte Arnold, President, MBA|
|Mark Ginski, President, Ph.D|
|Robert Schrepfer, VP, MBA|
|Daniel Raynor, Director|
|Stephen Carey, President|
|David Sullivan, VP, Ph.D|
|Karen Quinn, President|
|James Marken, VP|
|Peter Lankau, Director|
|Fred Holubow, Director|
|Tracy Marshbanks, Director|
|Arthur Przybyl, CEO|
|Thomas Penn, Director|
Stock Performance Indicators
Most of Macroaxis users are presently bullish on ANI Pharmaceuticals. What is your sentiment towards investing in ANI Pharmaceuticals? Are you bullish or bearish?
The main assumption in equity investing is that a higher degree of volatility (or risk) means a higher potential (or expected) return on investment. Conversely, investors who take on a low degree of risk have a low expection for return.
You can create optimal portfolios in USA market or optimize your existing portfolio in one of two ways: 1)
For any level of risk, select the one which has the highest expected return. 2)
For any expected return, select the one which has the lowest volatility.